Search
for
Sort by
Research 661–690 of 774
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Baricitinib: From Rheumatoid Arthritis to COVID‐19
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Successful treatment of alopecia universalis with abrocitinib: a case report
- Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
- Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
- Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
- Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- Alopecia universalis successfully treated with tofacitinib
- Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Efficacy of tofacitinib in pediatric alopecia universalis
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
- Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report
- Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib
- Successful Treatment of Extensive Ritlecitinib-Refractory Alopecia Areata with Upadacitinib